Low-dose Tacrolimus/Sirolimus and Steroid Withdrawal in Heart Recipients Is Highly Efficacious

Journal of Heart and Lung Transplantation

Volumn 26, Issue 6, 2007, Pages 598-603

  Meiser, Bruno ^a   Kaczmarek, Ingo ^a   Mueller, M ^a   Groetzner, Jan ^a   Weis, Michael ^b   Knez, Andreas ^b   Stempfle, Hans Ullrich ^b   Klauss, Volker ^b   Schmoeckel, Michael ^a   Reichart, Bruno ^a   Ueberfuhr, Peter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ADULT; ARTHRALGIA; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION SENSITIVITY; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MOUTH DISEASE; MUSCLE CRAMP; NEPHROTOXICITY; NEURALGIA; NEUROLOGICAL COMPLICATION; NEUROPATHY; OPEN STUDY; ORAL APHTHAE; PARESTHESIA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESS LEGS SYNDROME; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 34249317220     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.03.011     Document Type: Article

References (13)

1. Taylor D., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report-2005. J Heart Lung Transplant 24 (2005) 945-955
2. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus). Mechanism of action immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998) 335-340
3. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
4. Meiser B.M., and Reichart B. New agents and new strategies in immunosuppression after heart transplantation. Curr Opin Organ Transplant 7 (2002) 226-232
5. Groetzner J., Meiser B., Landwehr P., et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 77 (2004) 568-574
6. Meiser B., Reichart B., Adamidis I., Ueberfuhr P., and Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Transplantation 5 (2005) 827-831
7. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
8. Kaczmaraek I., Ertl B., Schmauss D., et al. Preventing cardiac allograft vasculopathy-long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 25 (2006) 550-556
9. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
10. Pham S.M., Jimenez J., Panos A.L., et al. The combined use of tacrolimus and sirolimus in clinical heart transplantation: intermediate-term results. Am J Transplant 5 suppl 11 (2005) 170
11. Lehmkuhl H., Ross H., Eisen H., and Valantine H. Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 37 (2005) 4145-4149
12. Meiser B.M., Groetzner J., Kaczmarek I., et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?. Transplantation 78 (2004) 591-598
13. Backman L.A. Post-transplant diabetes mellitus: the last 10 years with tacrolimus. Nephrol Dial Transplant 19 suppl 6 (2004) vi13-vi16